NDAINJECTIONINJECTABLEPriority Review
Approved
Oct 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
3/8 — Basic
Priority Review
NOVANTRONE (mitoxantrone hydrochloride) by Fresenius Kabi is clinical pharmacology: mechanism of action mitoxantrone, a dna-reactive agent that intercalates into deoxyribonucleic acid (dna) through hydrogen bonding, causes crosslinks and strand breaks. First approved in 2000.
Drug data last refreshed 15h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOVANTRONE (mitoxantrone hydrochloride) is a DNA-intercalating topoisomerase II inhibitor approved for acute myeloid leukemia (AML) and prostate cancer. It works by intercalating into DNA, causing strand breaks and crosslinks, while also inhibiting immune cell proliferation and antigen presentation. The drug demonstrates cytocidal activity against both proliferating and non-proliferating cells.
LOE Approaching
Product approaching loss of exclusivity with stable safety profile; commercial team likely focused on lifecycle extension or transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY: Mechanism of Action Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an…
Worked on NOVANTRONE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.